Evidence map›Paper›PMID 25232832›Full record

ArticlePLoS neglected tropical diseases2014

A new approach for monitoring ebolavirus in wild great apes.

Patricia E Reed, Sabue Mulangu, Kenneth N Cameron, Alain U Ondzie, Damien Joly, Magdalena Bermejo, Pierre Rouquet, Giulia Fabozzi, Michael Bailey, Zhimin Shen and 4 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Long-term wildlife mortality surveillance in northern Congo: a model for the detection of Ebola virus disease epizootics.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Patricia E ReedWildlife Conservation Society, Bronx, New York, New York, United States of America.
Sabue MulanguVaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America.
Kenneth N CameronWildlife Conservation Society, Bronx, New York, New York, United States of America.
Alain U OndzieWildlife Conservation Society, Bronx, New York, New York, United States of America.
Damien JolyWildlife Conservation Society, Bronx, New York, New York, United States of America.
Magdalena BermejoDepartamento Biologia Animal (Vertebrados), Facultad de Biologia, Universidad de Barcelona, Barcelona, Spain.
Pierre RouquetECOFAC, Libreville, Gabon.
Giulia FabozziVaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America.
Michael BaileyVaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America.
Zhimin ShenVaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America.
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Maryland, United States of America.
Beatrice HahnUniversity of Alabama at Birmingham, Birmingham, Alabama, United States of America.
William B KareshWildlife Conservation Society, Bronx, New York, New York, United States of America.
Nancy J SullivanVaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America.
Wildlife Conservation Society · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USFrederick National Laboratory for Cancer Research · USUniversitat de Barcelona · ESUniversity of Alabama at Birmingham · US

Funding

Natural SIV Reservoirs and Human Zoonotic RiskR01AI050529 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2001 to 2022
$6.1M
Molecular Epidemiology and Natural History of SIVcpzR01AI058715 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2004 to 2013
$6.1M
Natural SIV Reservoirs and Human Zoonotic RiskR37AI050529 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2008 to 2017
$5.7M
Intramural NIH HHSNIAID NIH HHS R01 AI050529NIAID NIH HHS R01 AI058715NIAID NIH HHS R01 AI50529NIAID NIH HHS R01 AI58715NIAID NIH HHS R37 AI050529
6 · The paper itself

Abstract

backgroundCentral Africa is a "hotspot" for emerging infectious diseases (EIDs) of global and local importance, and a current outbreak of ebolavirus is affecting multiple countries simultaneously. Ebolavirus is suspected to have caused recent declines in resident great apes. While ebolavirus vaccines have been proposed as an intervention to protect apes, their effectiveness would be improved if we could diagnostically confirm Ebola virus disease (EVD) as the cause of die-offs, establish ebolavirus geographical distribution, identify immunologically naïve populations, and determine whether apes survive virus exposure. METHODOLOGY/PRINCIPAL

findingsHere we report the first successful noninvasive detection of antibodies against Ebola virus (EBOV) from wild ape feces. Using this method, we have been able to identify gorillas with antibodies to EBOV with an overall prevalence rate reaching 10% on average, demonstrating that EBOV exposure or infection is not uniformly lethal in this species. Furthermore, evidence of antibodies was identified in gorillas thought previously to be unexposed to EBOV (protected from exposure by rivers as topological barriers of transmission). CONCLUSIONS/SIGNIFICANCE: Our new approach will contribute to a strategy to protect apes from future EBOV infections by early detection of increased incidence of exposure, by identifying immunologically naïve at-risk populations as potential targets for vaccination, and by providing a means to track vaccine efficacy if such intervention is deemed appropriate. Finally, since human EVD is linked to contact with infected wildlife carcasses, efforts aimed at identifying great ape outbreaks could have a profound impact on public health in local communities, where EBOV causes case-fatality rates of up to 88%.

Indexed as

AnimalsAntibodies, ViralApe DiseasesEbolavirusEpidemiological MonitoringFecesGorilla gorillaHemorrhagic Fever, EbolaAntibodies, Viral

Identifiers

PMID25232832
PMCPMC4169258
OpenAlexW1967361543

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.